Soluble ST2 levels in patients with cardiogenic and septic
shock are not predictors of mortality

J 2012

Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality

PAŘENICA, Jiří, Jan MALÁSKA, Jiří JARKOVSKÝ, Jolana LIPKOVÁ, Milan DASTYCH et. al.

Základní údaje

Originální název

Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality

Autoři

PAŘENICA, Jiří (203 Česká republika, garant, domácí), Jan MALÁSKA (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Jolana LIPKOVÁ (203 Česká republika, domácí), Milan DASTYCH (203 Česká republika, domácí), Kateřina HELÁNOVÁ (203 Česká republika, domácí), Jiří LITZMAN (203 Česká republika, domácí), Josef TOMANDL (203 Česká republika, domácí), Simona LITTNEROVÁ (203 Česká republika, domácí), Jana ŠEVČÍKOVÁ (203 Česká republika, domácí), Roman GÁL (203 Česká republika, domácí), Pavel ŠEVČÍK (203 Česká republika, domácí), Jindřich ŠPINAR (203 Česká republika, domácí) a Monika PÁVKOVÁ GOLDBERGOVÁ (203 Česká republika, domácí)

Vydání

EXPERIMENTAL & CLINICAL CARDIOLOGY, Kanada, Pulsus Group Inc, 2012, 1205-6626

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Kanada

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.100

Kód RIV

RIV/00216224:14110/12:00064953

Organizační jednotka

Lékařská fakulta

UT WoS

000312820300011

Klíčová slova anglicky

ACUTE MYOCARDIAL-INFARCTION; FAMILY-MEMBER ST2; NATRIURETIC PEPTIDE; RECEPTOR; IDENTIFICATION; EXPRESSION; BIOMARKER; PROTEIN; IL-33; SERA

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 12. 2013 10:47, prof. RNDr. Monika Pávková Goldbergová, Ph.D.

Anotace

V originále

OBJECTIVES: To assess sST2 levels in patients with cardiogenic shock (CS) and septic shock (SS), and to evaluate the prognostic value of sST2 for short-term mortality. METHODS: The present prospective observational study evaluated 32 patients with CS, 17 patients with SS and 61 patients with ST segment elevation myocardial infarction (STEMI)(control group). Samples of serum were collected eight times and the follow-up time was three months. RESULTS: sST2 levels were elevated from admission in SS patients relative to patients with CS and STEMI, who exhibited peak sST2 levels 24 h after admission. On admission, CS patients had a median (5th percentile; 95th percentile) sST2 level of 62.5 pg/mL (8.3 pg/mL; 315.8 pg/mL) and SS patients had a median sST2 level of 216.4 pg/mL (46.8 pg/mL; 364.4 pg/mL). ROC analysis found sST2 to be a biomarker that could distinguish between CS and SS at admission (area under the curve [AUC] 0.813; P<0.01) with a cut-off value of 210.4 pg/mL. Patients with STEMI had significantly lower sST2 levels at admission (20.3 pg/mL (4.2 pg/mL; 339.8 pg/mL) compared with CS patients. The AUC of the ROC analysis was 0.671 (P=0.007) for the detection of CS in patients with STEMI. Only a weak correlation was observed between sST2 and B-type natriuretic peptide (r=0.376, P=0.05) and sST2 and N-terminal pro-B-type natriuretic peptide (r=0.496, P=0.019). No statistically significant differences were observed in sST2 levels in patients with CS and SS relative to three-month mortality. CONCLUSION: Levels of sST2 at admission are significantly higher in patients with SS compared with CS. sST2 could be a diagnostic marker to distinguish SS and CS as well as CS and STEMI at the time of admission. Levels of sST2 are related to levels of natriuretic peptides in CS but not in SS. sST2 levels are not a suitable prognostic marker for patients with CS and SS.

Návaznosti

NS9894, projekt VaV

Název: Role SIRS, NO a oxidativního stresu v rozvoji šokového stavu a mitochondriální dysfunkce jako podklad multiorgánového selhání

Investor: Ministerstvo zdravotnictví ČR, Role SIRS, NO a oxidativního stresu v rozvoji šokového stavu a mitochondriální dysfunkce jako podklad multiorgánového selhání

Citovat

PAŘENICA, Jiří, Jan MALÁSKA, Jiří JARKOVSKÝ, Jolana LIPKOVÁ, Milan DASTYCH, Kateřina HELÁNOVÁ, Jiří LITZMAN, Josef TOMANDL, Simona LITTNEROVÁ, Jana ŠEVČÍKOVÁ, Roman GÁL, Pavel ŠEVČÍK, Jindřich ŠPINAR a Monika PÁVKOVÁ GOLDBERGOVÁ. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. EXPERIMENTAL & CLINICAL CARDIOLOGY. Kanada: Pulsus Group Inc, 2012, roč. 17, č. 4, s. 205-209. ISSN 1205-6626.

@article{1086406,
   author = {Pařenica, Jiří and Maláska, Jan and Jarkovský, Jiří and Lipková, Jolana and Dastych, Milan and Helánová, Kateřina and Litzman, Jiří and Tomandl, Josef and Littnerová, Simona and Ševčíková, Jana and Gál, Roman and Ševčík, Pavel and Špinar, Jindřich and Pávková Goldbergová, Monika},
   article_location = {Kanada},
   article_number = {4},
   keywords = {ACUTE MYOCARDIAL-INFARCTION; FAMILY-MEMBER ST2; NATRIURETIC PEPTIDE; RECEPTOR; IDENTIFICATION; EXPRESSION; BIOMARKER; PROTEIN; IL-33; SERA},
   language = {eng},
   issn = {1205-6626},
   journal = {EXPERIMENTAL & CLINICAL CARDIOLOGY},
   title = {Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality},
   url = {http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=T1@@NmFFBGL6hjE5c7H&page=1&doc=2},
   volume = {17},
   year = {2012}
}

TY  - JOUR
ID  - 1086406
AU  - Pařenica, Jiří - Maláska, Jan - Jarkovský, Jiří - Lipková, Jolana - Dastych, Milan - Helánová, Kateřina - Litzman, Jiří - Tomandl, Josef - Littnerová, Simona - Ševčíková, Jana - Gál, Roman - Ševčík, Pavel - Špinar, Jindřich - Pávková Goldbergová, Monika
PY  - 2012
TI  - Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality
JF  - EXPERIMENTAL & CLINICAL CARDIOLOGY
VL  - 17
IS  - 4
SP  - 205-209
EP  - 205-209
PB  - Pulsus Group Inc
SN  - 12056626
KW  - ACUTE MYOCARDIAL-INFARCTION
KW  - FAMILY-MEMBER ST2
KW  - NATRIURETIC PEPTIDE
KW  - RECEPTOR
KW  - IDENTIFICATION
KW  - EXPRESSION
KW  - BIOMARKER
KW  - PROTEIN
KW  - IL-33
KW  - SERA
UR  - http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=T1@@NmFFBGL6hjE5c7H&page=1&doc=2
L2  - http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=T1@@NmFFBGL6hjE5c7H&page=1&doc=2
N2  - OBJECTIVES: To assess sST2 levels in patients with cardiogenic shock (CS) and septic shock (SS), and to evaluate the prognostic value of sST2 for short-term mortality. METHODS: The present prospective observational study evaluated 32 patients with CS, 17 patients with SS and 61 patients with ST segment elevation myocardial infarction (STEMI)(control group). Samples of serum were collected eight times and the follow-up time was three months. RESULTS: sST2 levels were elevated from admission in SS patients relative to patients with CS and STEMI, who exhibited peak sST2 levels 24 h after admission. On admission, CS patients had a median (5th percentile; 95th percentile) sST2 level of 62.5 pg/mL (8.3 pg/mL; 315.8 pg/mL) and SS patients had a median sST2 level of 216.4 pg/mL (46.8 pg/mL; 364.4 pg/mL). ROC analysis found sST2 to be a biomarker that could distinguish between CS and SS at admission (area under the curve [AUC] 0.813; P<0.01) with a cut-off value of 210.4 pg/mL. Patients with STEMI had significantly lower sST2 levels at admission (20.3 pg/mL (4.2 pg/mL; 339.8 pg/mL) compared with CS patients. The AUC of the ROC analysis was 0.671 (P=0.007) for the detection of CS in patients with STEMI. Only a weak correlation was observed between sST2 and B-type natriuretic peptide (r=0.376, P=0.05) and sST2 and N-terminal pro-B-type natriuretic peptide (r=0.496, P=0.019). No statistically significant differences were observed in sST2 levels in patients with CS and SS relative to three-month mortality. CONCLUSION: Levels of sST2 at admission are significantly higher in patients with SS compared with CS. sST2 could be a diagnostic marker to distinguish SS and CS as well as CS and STEMI at the time of admission. Levels of sST2 are related to levels of natriuretic peptides in CS but not in SS. sST2 levels are not a suitable prognostic marker for patients with CS and SS.
ER  -

PAŘENICA, Jiří, Jan MALÁSKA, Jiří JARKOVSKÝ, Jolana LIPKOVÁ, Milan DASTYCH, Kateřina HELÁNOVÁ, Jiří LITZMAN, Josef TOMANDL, Simona LITTNEROVÁ, Jana ŠEVČÍKOVÁ, Roman GÁL, Pavel ŠEVČÍK, Jindřich ŠPINAR a Monika PÁVKOVÁ GOLDBERGOVÁ. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. \textit{EXPERIMENTAL \&{} CLINICAL CARDIOLOGY}. Kanada: Pulsus Group Inc, 2012, roč.~17, č.~4, s.~205-209. ISSN~1205-6626.

Podrobný výpis o publikaci